|
|
Article: Celgene Corporation Reports Record Operating Performance for 2005.
- Article from:
- PR Newswire
- Article date:
- January 26, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
42% Increase in Total Revenue For 2005 Versus Prior Year
35% Annual Increase in Total Product Sales For 2005
100% Increase in Adjusted Operating Income Year-Over-Year
Fourth Quarter Highlights:
* REVLIMID(R) NDA Granted FDA Approval for MDS Deletion 5q
* REVLIMID sNDA Submitted to FDA for Relapsed or Refractory Multiple Myeloma
* REVLIMID MAA Filing Under Review at EMEA for MDS Deletion 5q